Pricing Log in Create free account

Adial Pharmaceuticals, Inc. (ADIL) vs COSCIENS Biopharma Inc. (CSCIF)

Adial Pharmaceuticals, Inc. and COSCIENS Biopharma Inc. are both Biotechnology companies. Adial Pharmaceuticals, Inc. and COSCIENS Biopharma Inc. are of similar size ($8.6M and $8.3M). Adial Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; COSCIENS Biopharma Inc. trades at 1.0×. COSCIENS Biopharma Inc. has the higher net margin (75.1% vs 0.00%) and the lower return on invested capital (−40.6% vs 0.00%). Across the 12 metrics below, Adial Pharmaceuticals, Inc. leads on 7 and COSCIENS Biopharma Inc. on 5.

Valuation

Metric ADIL CSCIF Biotechnology median
P/E n/m 1.03 8.50
P/S n/m 0.78 9.71
P/B n/m 0.46 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.22 n/m 0.64
EV/Sales n/m 0.17 9.21
Earnings yield (461.83%) 96.93% (33.15%)
Free cash flow yield (68.29%) (45.48%) (25.50%)

Profitability

Metric ADIL CSCIF Biotechnology median
Gross margin 0.00% 46.48% 65.16%
Operating margin 0.00% (71.13%) 0.00%
Net margin 0.00% 75.11% 0.00%
Free cash flow margin 0.00% (40.36%) 0.00%
Return on equity 352.60% 59.74% (56.36%)
Return on assets (322.10%) 28.24% (48.04%)
Return on invested capital 0.00% (40.56%) 0.00%

Growth

Metric ADIL CSCIF Biotechnology median
Revenue growth (TTM) — (3.02%) 6.02%
EPS growth (last fiscal year) 82.46% 44.86% 30.26%
Revenue growth, 5-year CAGR — 15.47% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADIL CSCIF Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.63 4.33 4.72
Net debt to EBITDA 0.75 0.78 0.96

Dividend

Metric ADIL CSCIF Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADIL CSCIF Biotechnology median
Market cap 8.25m 8.57m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack